Actinium Pharmaceuticals

ATNM · United States

Share price · ATNM

$1.08+0.00 (+0.00%) 3M

close as of 2026-11-18 · 24h delayed · vol 327K (1.3x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when ATNM's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 18 Nov 2026-20.0%
  2. 22 Oct 2026+15.9%
  3. 19 Oct 2026+16.8%
  4. 8 Sep 2026+19.4%

    Nothing announced by ATNM that day or the session before.

  5. 13 Aug 2026+17.4%

    Nothing announced by ATNM that day or the session before.

  6. 5 Aug 2026-7.5%

    Nothing announced by ATNM that day or the session before.

  7. 29 May 2026+9.6%
  8. 22 Apr 2026-7.9%
  9. 20 Apr 2026+10.8%
  10. 15 Apr 2026+14.5%

    Nothing announced by ATNM that day or the session before.

Share of unusual movement by asset

For each asset, the share of ATNM's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
Lintuzumab-Ac225
events and moves
149%
131I-apamistamab
events and moves
1shown from 8 days
Assets with fewer than 8 event days, together—0%
Other company news (earnings, financing, releases naming no asset)—33%
Sessions with no dated event—58%

Assets

(2 total)
2Total Assets
0Approved
1Phase 3 / Filed
1Phase 1–2 / Early
1Diseases
Showing 2 of 2 assets
Target & Modality
Phase 3
CD45Monoclonal antibody
Acute Myeloid Leukemia
Phase 2
CD33Radiopharmaceutical
Acute Myeloid Leukemia

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2029 (1)
February 2029 (1)
131I-apamistamabPhase 2/3Acute Leukemia, Myeloid Leukemia, Acute Myelogenous Leukemia, Acute Myeloid Leukemia, Acute Myeloid Leukemia, in Relapse …
Est. primary completion 2029-02 · NCT07157514 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

February 2023Topline result131I-apamistamabPhase 3 SIERRA results: durable complete remission primary endpoint met; overall survival not improved

Financial reports

Quarterly & interim (15)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2$35M$5.4M$37M—-$5.2M operating cash flowreport ↗
View 14 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q1—$4.2M$42M$5.5M-$5.9M operating cash flowreport ↗
2025-Q3$0.1M$4.3M$54M$5.1M-$6.3M operating cash flowreport ↗
2025-Q2—$4.9M$60M$6.9M-$5.4M operating cash flowreport ↗
2025-Q1—$7.7M$66M$16M-$7.6M operating cash flowreport ↗
2024-Q3—$9.8M$79M$12M-$12M operating cash flowreport ↗
2024-Q2—$8.8M$86M$11M-$8.0M operating cash flowreport ↗
2024-Q1—$6.6M$84M$8.7M-$7.4M operating cash flowreport ↗
2023-Q3—$12M$83M$13M-$11M operating cash flowreport ↗
2023-Q2—$11M$92M$15M-$14M operating cash flowreport ↗
2023-Q1—$7.8M$95M$11M-$15M operating cash flowreport ↗
2022-Q3$0.1M$6.8M$113M$9.5M-$5.7M operating cash flowreport ↗
2022-Q2$0.1M$4.7M$117M$7.8M$28M operating cash flowreport ↗
2022-Q1$0.9M$4.4M$72M$5.1M-$5.8M operating cash flowreport ↗
2021-Q3$0.2M$4.7M$82M$6.4M-$5.6M operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$0.1M$21M$48M$8.5M-$25M operating cash flowreport ↗

Actinium Pharmaceuticals reported revenue of $0.09M for fiscal year 2025, with no prior-year revenue disclosed. R&D spend was $21.12M, down 29.7% YoY, and cash and equivalents totaled $48.33M. The company reported a net loss of $33.89M, with a quarterly net burn of $33.89M.

The clinical-stage radiopharmaceutical company is advancing a pipeline focused on targeted radiotherapies, including ATNM-400 for solid tumors, Actimab-A for AML/MDS and MDSC-mediated resistance to checkpoint inhibitors, and the conditioning agents Iomab-B and Iomab-ACT. Management highlighted FDA alignment on Phase 2/3 trial designs for Iomab-B and Actimab-A plus CLAG-M, active partnership discussions for the hematology programs, and expected initial data from an Actimab-A basket trial in 2H:2026. A radiopharmaceutical manufacturing facility is expected to be commissioned in 2H:2026.

View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY—$30M$73M$9.6M-$33M operating cash flowreport ↗
2023-FY$0.1M$39M$77M$12M-$47M operating cash flowreport ↗
2022-FY$1.0M$23M$110M$8.3M$8.6M operating cash flowreport ↗
2021-FY$1.1M$18M$78M$6.2M-$21M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 0 purchases (—), 0 sales (—). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-10-14David Matthew T · Chief Financial OfficerAward / grant250,000——Form 4
2026-10-14David Matthew T · Chief Financial OfficerAward / grant (derivative)250,000——Form 4
2026-09-02Chell Jeffrey W. · directorAward / grant61,600——Form 4
2026-09-02Steinhart Richard I · directorAward / grant62,800——Form 4
2026-09-02SETH SANDESH · director, Chief Executive OfficerAward / grant753,600——Form 4
2026-09-02Almenoff June Sherie · directorAward / grant18,000——Form 4
2026-09-02Nicholson, C. David · directorAward / grant62,800——Form 4
2026-09-02Shetty Ajit · directorAward / grant61,600——Form 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 54 reporting institutions held 5.3M shares ($4.6M, 16.9% of shares outstanding).

#InstitutionSharesValue
1VANGUARD CAPITAL MANAGEMENT LLC1,255,516$1.2M
2MILLENNIUM MANAGEMENT LLC564,600$562K
3RENAISSANCE TECHNOLOGIES LLC471,600$469K
4BlackRock, Inc.371,210$369K
5TWO SIGMA INVESTMENTS, LP337,168$336K
6GEODE CAPITAL MANAGEMENT, LLC336,073$335K
7GAGNON SECURITIES LLC201,300$200K
8VANGUARD FIDUCIARY TRUST CO160,265$159K
9STATE STREET CORP126,215$126K
10SUSQUEHANNA INTERNATIONAL GROUP, LLP123,998$123K
11Gen-Wealth Partners Inc107,111$107K
12NORTHERN TRUST CORP75,855$75K
13GOLDMAN SACHS GROUP INC70,241$70K
14BRIDGEWAY CAPITAL MANAGEMENT, LLC40,000$40K
15TWO SIGMA SECURITIES, LLC35,887$36K